Flen Health taps AGC Biologics to make enzymes for next-generation wound treatment

• AGC Biologics won a contract from Flen Health to develop and manufacture recombinant lactoperoxidase and glucose oxidase for a next-generation wound treatment.
• Work will be led by the Heidelberg facility, covering process development, scale-up, and GMP production to support an IND filing and Phase II trials.
• Manufacturing is planned at 100-liter and 1,000-liter scale using a Pichia pastoris expression system.
• Program follows a feasibility collaboration launched in July 2025, moving into full GMP development and clinical-scale supply.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AGC Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240255OMX_____CNEWS_EN_GNW9832002_en) on September 24, 2026, and is solely responsible for the information contained therein.